Wall Street analysts expect FibroGen Inc (NASDAQ:FGEN) to report $28.23 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for FibroGen’s earnings, with estimates ranging from $27.40 million to $29.00 million. FibroGen posted sales of $26.89 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 5%. The firm is scheduled to report its next quarterly earnings results on Tuesday, May 8th.
On average, analysts expect that FibroGen will report full-year sales of $28.23 million for the current fiscal year, with estimates ranging from $127.00 million to $225.00 million. For the next year, analysts expect that the company will report sales of $358.32 million per share, with estimates ranging from $281.00 million to $464.80 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow FibroGen.
A number of research analysts have weighed in on the company. ValuEngine lowered FibroGen from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Zacks Investment Research lowered FibroGen from a “hold” rating to a “sell” rating in a report on Monday, March 5th. BidaskClub lowered FibroGen from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Leerink Swann reaffirmed an “outperform” rating and set a $88.00 target price (up previously from $80.00) on shares of FibroGen in a report on Wednesday, February 28th. Finally, TheStreet raised FibroGen from a “d” rating to a “c-” rating in a report on Tuesday, February 27th. Two analysts have rated the stock with a sell rating, three have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. FibroGen has an average rating of “Hold” and a consensus target price of $66.67.
In other news, VP Pat Cotroneo sold 49,500 shares of FibroGen stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $55.96, for a total transaction of $2,770,020.00. Following the completion of the sale, the vice president now owns 207,392 shares in the company, valued at approximately $11,605,656.32. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider K Peony Yu sold 10,000 shares of FibroGen stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $62.00, for a total value of $620,000.00. Following the sale, the insider now owns 152,086 shares of the company’s stock, valued at approximately $9,429,332. The disclosure for this sale can be found here. Insiders have sold a total of 448,237 shares of company stock valued at $23,351,636 in the last ninety days. Insiders own 13.60% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of FGEN. Eagle Asset Management Inc. bought a new stake in shares of FibroGen during the 3rd quarter valued at about $46,158,000. First Trust Advisors LP lifted its position in FibroGen by 1,058.4% in the 4th quarter. First Trust Advisors LP now owns 776,640 shares of the biopharmaceutical company’s stock worth $36,813,000 after buying an additional 709,598 shares during the last quarter. Carillon Tower Advisers Inc. bought a new stake in FibroGen in the 4th quarter worth approximately $282,486,000. Farallon Capital Management LLC lifted its position in FibroGen by 50.7% in the 4th quarter. Farallon Capital Management LLC now owns 1,657,500 shares of the biopharmaceutical company’s stock worth $78,566,000 after buying an additional 557,500 shares during the last quarter. Finally, BlackRock Inc. lifted its position in FibroGen by 4.0% in the 4th quarter. BlackRock Inc. now owns 6,326,075 shares of the biopharmaceutical company’s stock worth $299,855,000 after buying an additional 244,617 shares during the last quarter. Hedge funds and other institutional investors own 61.39% of the company’s stock.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.